Drugs / Licensed mRNA vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06147063 Comparator | Nov 2023 → Apr 2024 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Licensed mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06147063 ↗ |
| Modality | Messenger RNA (mRNA) | “licensed SARS-CoV-2 mRNA vaccine” NCT06147063 ↗ |